It is important to evaluate HIV-1-specific immunological responses elicited by therapeutic or prophylactic vaccines using precise, standardised assays, so that the immunogenicity and putative efficacy of candidate vaccines may be compared. Different well-validated assays must be used to quantitate specific responses, to determine which particular strategies may be efficacious.